Metagenomi, Inc. Common Stock

NASDAQ: MGX · Healthcare · Biotechnology

PublicHQ Emeryville, CIK 0001785279Reports USD

#521 of 1,394 Healthcare companies by revenuebottom-quartile growth

EA Score

39D

FH 44DQ 24GM —SS 69

v0.1 · 55/100 weight · provisional

↑ listing tenure, balance-sheet leverage · ↓ disclosure history, revenue growth (YoY)

Methodology →

Revenue TTM

$22.3M

Rev growth YoY (TTM)

-50.7%

Net income (FY)

-$87.9M

Employees

202

Market cap

$47.4M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$25.2M$25.2M2025

Net income-$87.9M-$87.9M2025

Operating income-$96.0M-$96.0M2025

Total assets$221.1M$221.1M2025

Liabilities$62.5M$62.5M2025

Equity$158.6M$158.6M2025

Revenue trend

FY2024 – FY2025 · USD

$44.8M

FY24

$52.3M

FY24

$25.2M

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Metagenomi, Inc. Common Stock booked $25.2M in FY2025 revenue, contracting 52% year over year — slower than 83% of Healthcare companies we track, at a -348.5% net margin.

Peers · Healthcare

Horizon Space Acquisition II Corp.——Vicapsys Life Sciences, Inc.——PDS Biotechnology Corporation——Decibel Cannabis Company Inc.62C

Key facts

CEOJian Irish

SectorHealthcare

IndustryBiotechnology

HeadquartersEmeryville, null

ExchangeNASDAQ: MGX

Employees202

IPO date2006-04-06

Latest filings

8-K2026-06-10 8-K2026-05-11 10-Q2026-05-11 DEF 14A2026-04-27 10-K2026-03-05 8-K2026-03-05 8-K2026-01-12 10-Q2025-11-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.